Table 2.

Progression-free survival and overall survival from KEYNOTE-826 trial

	PD-L1 CPS ≥1		All-Comer		PD-L1 CPS ≥10
	Pembro + Chemo n = 273	Pbo + Chemo n = 275	Pembro + Chemo n = 308	Pbo + Chemo n = 309	Pembro + Chemo n = 158	Pbo + Chemo n = 159
OS, median, mo	28.6	16.5	26.4	16.8	29.6	17.4
24-mo OS rate, %	53.5	39.4	52.1	38.7	54.4	42.5
OS, HR (95% CI)	0.60 (0.49–0.74); P< 0.0001		0.63 (0.52–0.77); P< 0.0001		0.58 (0.44–0.78); P< 0.0001
PFS,median, mo	10.5	8.2	10.4	8.2	10.4	8.1
12-mo PFS rate, %	45.6	33.7	44.7	33.1	44.7	33.5
PFS, HR (95% CI)	0.58 (0.47–0.71); P< 0.0001		0.61 (0.50–0.74); P< 0.0001		0.52 (0.40–0.68); P< 0.0001

PFS: progression-free survival; OS: overall survival; PD-L1: programmed death-ligand 1; CPS: Combined Positive Score; CI: confidence interval; HR: Hazard Ratio

Reprinted with permission from J Clin Oncol 41, 2023 (suppl 16; abstr 5500) Monk B, Colombo N, Tewari K, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.